The Latest Breaking News from Tonix Pharmaceuticals Holding Corp

Tonix Pharma's Drug Gets FDA Nod For Chronic Pain Condition, First New Therapy In Over 15 Years

On Friday, the U.S. Food and Drug Administration (FDA) approved Tonix Pharmaceuticals Holding Corp.’s (NASDAQ:TNXP) Tonmya (cyclobenzaprine HCl sublingual tablets) for fibromyalgia in adults.

Benzinga · Aug 18, 2025

What's Going On With Tonix Pharmaceuticals (TNXP) Stock?

Shares of Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) have rallied 30% over the past five sessions, though are marginally lower Thursday afternoon, as investors anticipate a key catalyst for the company.

Benzinga · Aug 14, 2025

Why Tonix Pharmaceuticals (TNXP) Stock Is Climbing This Week

Shares of Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) are building on recent gains, trading higher as investor focus intensifies on a key, upcoming catalyst. Here’s what investors need to know.

Benzinga · Aug 13, 2025

Why Tonix Pharmaceuticals Stock Is Soaring

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) shares are trading higher Wednesday after the company announced that the United States Patent and Trademark Office issued a patent to Tonix titled, "Synthetic Chimeric Poxviruses."

Benzinga · Jun 1, 2022

Tonix Pharma Starts New Pivotal Trial For TNX-102 SL In Fibromyalgia Patients

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) has 

Benzinga · Apr 7, 2022

Executives Buy More Than $1M Of 5 Penny Stocks

The Dow Jones jumped around 200 points on Tuesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or…

Benzinga · Mar 29, 2022

Tonix Says Fibromyalgia Candidate Failed To Achieve Statistical Significance Over Placebo

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) says that as expected, TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 

Benzinga · Mar 21, 2022

Tonix Pharma Collaborates With Massachusetts General Hospital For TNX-1900 In Binge Eating Disorder

Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) has announced an agreement with Massachusetts General Hospital to evaluate TNX-1900 (intranasal potentiated oxytocin) in a Phase 2 trial as a potential treatment for binge eating disorder.  The Phase 2 clinical trial is expected to start in 2H of 2022. TNX-1900 is also in development for the treatment…

Benzinga · Mar 7, 2022

Tonix Pharma Inks Research Pact For Oxytocin In Eating Disorder

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) has 

Benzinga · Feb 28, 2022